Thomas P. Pacatte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas P. Pacatte has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aldin Turan
Division of Infectious Diseases, Allergy & Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA
1 shared publication - Azra Blazevic
Division of Infectious Diseases, Allergy & Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA
1 shared publication - Daniel Fredric Hoft
Affiliations Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University Medical Center, St. Louis, Missouri, United States of America, Department of Molecular Microbiology and Immunology, Saint Louis University Medical Center, St. Louis, Missouri, United States of America
1 shared publication - Kathleen R. Lottenbach
Division of Infectious Diseases, Allergy & Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA
1 shared publication - Michelle C. Mitchell
Division of Infectious Diseases, Allergy & Immunology, Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA
1 shared publication - Robert B. Belshe
Health Science Center, Division of Infectious Diseases, Saint Louis University, 3035 Vista at Grand Blvd, St.-Louis, MO 63110, USA
1 shared publication
Latest Publications
- 1 January 2017
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 24 (1)
Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults
Both live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) induce protective immunity against influenza. There is evidence that LAIV induces superior protection in children, whereas IIV may induce superior protection in adults. The immune mechanisms responsible for these differences have not been identified. We previously compared LAIV and IIV in young children of 6 to 36 months of age, and we demonstrated that while both induced similar hemagglutination inhibition (HAI) antibody responses, only LAIV induced significant increases in T cell responses. In the present study, 37 healthy adult subjects of 18 to 49 years of age were randomized to receive seasonal influenza vaccination with LAIV or IIV. Influenza virus-specific HAI, T cell, and secretory IgA (sIgA) responses were studied pre- and postvaccination. In contrast to the responses seen in young children, LAIV induced only minimal increases in serum HAI responses in adults, which were significantly lower than the responses induced by IIV. Both LAIV and IIV similarly induced only transient T cell responses to replication-competent whole virus in adults. In contrast, influenza virus-specific sIgA responses were induced more strongly by LAIV than by IIV. Our previous studies suggest that LAIV may be more protective than IIV in young children not previously exposed to influenza virus or influenza vaccines due to increased vaccine-induced T cell and/or sIgA responses. Our current work suggests that in adults with extensive and partially cross-reactive preexisting influenza immunity, LAIV boosting of sIgA responses to hemagglutinin (HA) and non-HA antigenic targets expressed by circulating influenza virus strains may be an important additional mechanism of vaccine-induced immunity.
- 1 January 2017
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 24 (1)
Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults
Both live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) induce protective immunity against influenza. There is evidence that LAIV induces superior protection in children, whereas IIV may induce superior protection in adults. The immune mechanisms responsible for these differences have not been identified. We previously compared LAIV and IIV in young children of 6 to 36 months of age, and we demonstrated that while both induced similar hemagglutination inhibition (HAI) antibody responses, only LAIV induced significant increases in T cell responses. In the present study, 37 healthy adult subjects of 18 to 49 years of age were randomized to receive seasonal influenza vaccination with LAIV or IIV. Influenza virus-specific HAI, T cell, and secretory IgA (sIgA) responses were studied pre- and postvaccination. In contrast to the responses seen in young children, LAIV induced only minimal increases in serum HAI responses in adults, which were significantly lower than the responses induced by IIV. Both LAIV and IIV similarly induced only transient T cell responses to replication-competent whole virus in adults. In contrast, influenza virus-specific sIgA responses were induced more strongly by LAIV than by IIV. Our previous studies suggest that LAIV may be more protective than IIV in young children not previously exposed to influenza virus or influenza vaccines due to increased vaccine-induced T cell and/or sIgA responses. Our current work suggests that in adults with extensive and partially cross-reactive preexisting influenza immunity, LAIV boosting of sIgA responses to hemagglutinin (HA) and non-HA antigenic targets expressed by circulating influenza virus strains may be an important additional mechanism of vaccine-induced immunity.